Peripheral Magnetic Stimulation (PMS) Effects on Somatosensory Perception in Patients with Upper Limb Amputation
Launched by SKOLKOVO INSTITUTE OF SCIENCE AND TECHNOLOGY · Feb 3, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called peripheral magnetic stimulation (PMS) to see how it affects people with upper limb amputations who experience phantom limb pain. Phantom limb pain is the sensation of pain coming from a limb that is no longer there. The researchers want to understand how magnetic pulses can create different sensations and how these sensations relate to brain activity. They are looking for healthy volunteers and those with upper limb amputations, ages 65 to 74 and 23 to 740 years old, who are willing to participate.
Participants will receive magnetic pulses of different strengths while their feelings and brain activity are recorded. To join the study, healthy volunteers must be in good health and not have certain medical conditions, such as epilepsy or severe psychiatric disorders. Participants with amputations will also be screened for similar health issues. This trial aims to gather information that could help develop new treatments for those suffering from phantom limb sensations, making it an important step toward improving patient care in the future.
Gender
ALL
Eligibility criteria
- For Healthy Volunteers:
- Inclusion Criteria:
- • 1. Availability of signed written informed consent.
- • 2. Absence of somatic and psychiatric diseases (more details in the exclusion criteria)
- • 3. Ability and willingness to comply with the requirements of this protocol. Inclusion Criteria
- Exclusion Criteria:
- • 1. History of epilepsy (participant, participant's close relatives)
- • 2. Presence of metal or/and electric stimulators and/or implants in participant's body
- • 3. Presence of psychiatric disorders (including a history of), severe depression, suicidal tendencies, or a history of suicide attempts.
- • 4. History of cancer.
- • 5. Complicated traumatic brain injury (TBI) or a history of stroke.
- • 6. Drug addiction (including a history of).
- • 7. Congenital anomaly of upper limb development.
- • 8. Anomalies in the development of the central and peripheral nervous systems.
- • 9. Pregnancy
- For stroke patients:
- • 1. History of epilepsy (participant, participant's close relatives)
- • 2. Presence of metal or/and electric stimulators and/or implants in participant's body
- • 3. Presence of psychiatric disorders (including a history of), severe depression, suicidal tendencies, or a history of suicide attempts.
- • 4. History of cancer.
- • 5. Complicated traumatic brain injury (TBI) or a history of stroke.
- • 6. Drug addiction (including a history of).
- • 7. Congenital anomaly of upper limb development.
- • 8. Anomalies in the development of the central and peripheral nervous systems.
- • 9. Pregnancy
- • 10. Presence of severe somatic pathology
- • 11. Presence of severe orthopedic deformity in the limb above the level of amputation.
- • 12. Purulent-septic pathology.
About Skolkovo Institute Of Science And Technology
The Skolkovo Institute of Science and Technology (Skoltech) is a prestigious research and educational institution located in Russia, dedicated to advancing innovation in science and technology. Established in collaboration with the Massachusetts Institute of Technology (MIT), Skoltech focuses on interdisciplinary research, fostering entrepreneurship, and cultivating a new generation of scientists and engineers. The institute emphasizes the integration of cutting-edge research with practical applications, particularly in areas such as biotechnology, information technology, and energy. As a clinical trial sponsor, Skoltech is committed to conducting high-quality research that adheres to rigorous ethical standards and contributes to the advancement of health and medical sciences.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported